Clinical trials: sponsored by Ionis Pharmaceuticals, Inc.
End-stage Renal Disease (ESRD)
A Study of Safety, PK, & PD of ISIS 416858 Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis
Evaluation of safety, tolerability, PK and PD of ISIS 416858 in patients with end-stage renal disease (ESRD) receiving chronic hemodialysis.
- Trial name
- NCT02553889
- Testing
- ISIS 416858
- Where
- 8 sites in Canada
- Volunteers
- 49 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Type 2 Diabetes Mellitus
Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes
The purpose of this study is to evaluate the efficacy, safety and tolerability of ISIS-GCGRRx in combination with metformin versus placebo + metformin
- Trial name
- NCT01885260
- Testing
- ISIS-GCGRRx - Dose Level 1, ISIS-GCGRRx - Dose Level 2
- Where
- 24 sites in United States, South Africa
- Volunteers
- 77 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Paroxysmal Atrial Fibrillation
Antiarrhythmic and Symptomatic Effect of ISIS CRP Rx Targeting CRP in Paroxysmal Atrial Fibrillation
The purpose of this study is to evaluate whether treatment with ISIS CRP Rx can reduce AF (Atrial Fibrillation) burden (percentage of time spent in AF) in subjects with paroxysmal AF
- Trial name
- ASET (NCT01710852)
- Testing
- ISIS CRP Rx
- Where
- United Kingdom
- Volunteers
- 7 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Type 2 Diabetes Mellitus
Safety, Tolerability and Efficacy of ISIS-GCCRRx in Type 2 Diabetes
The purpose of this study is to evaluate the efficacy, safety and tolerability of ISIS-GCCRRx in combination with metformin versus placebo + metformin
- Trial name
- NCT01968265
- Testing
- ISIS-GCCRRx
- Where
- 14 sites in Canada, Romania and 1 more
- Volunteers
- 38 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Type 2 Diabetes Mellitus, Obese
Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes
The purpose of this study is to evaluate the safety, tolerability, and efficacy of ISIS-PTP1BRx + oral antidiabetic drug/s (metformin and/or sulfonylurea) versus placebo + oral antidiabetic drug/s.
- Trial name
- NCT01918865
- Testing
- ISIS-PTP1BRx, daily OAD (metformin and/or sulfonylurea)
- Where
- 21 sites in Argentina, Canada and 1 more
- Volunteers
- 92 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Venous Thromboembolism
Active Comparator-Controlled Study to Assess Safety and Efficacy of ISIS-FXIRx in Total Knee Arthroplasty
The purpose of this study is: To assess the safety and efficacy profile of ISIS-FXIRx, including incidence of bleeding and VTE, in patients undergoing total knee arthroplasty.
- Trial name
- NCT01713361
- Testing
- ISIS-FXIRx Dose #2, ISIS-FXIRx Dose #3, Enoxaparin
- Where
- 21 sites in Bulgaria, Canada and 3 more
- Volunteers
- 315 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Rheumatoid Arthritis
Safety, Tolerability, and Pharmacodynamic Study of ISIS CRP Rx in Rheumatoid Arthritis
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of ISIS CRP Rx and its effects on CRP and other pharmacodynamic measures, versus placebo, in subjects with active rheumatoid arthritis.
- Trial name
- NCT01414101
- Where
- 10 sites in Canada, Russia
- Volunteers
- 51 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Familial Amyotrophic Lateral Sclerosis
Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations
This study will test the safety, tolerability and pharmacokinetics of single doses of ISIS 333611 administered into the spinal canal as 12 hour infusions.
- Trial name
- SOD-1 (NCT01041222)
- Testing
- ISIS 333611
- Where
- 4 sites in United States
- Volunteers
- 33 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Type 2 Diabetes Mellitus
Safety, Tolerability and Activity Study of Multiple Doses of ISIS-SGLT2Rx in Healthy Volunteers
The primary purpose of this trial is to assess the safety and tolerability of ISIS-SGLT2Rx when given at increasing single doses and to assess the safety and tolerability of the same doses when given multiple times.
- Trial name
- NCT00836225
- Testing
- ISIS 388626
- Where
- Netherlands
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Ionis Pharmaceuticals, Inc.
Inflammatory Diseases
Safety and Tolerability of Single and Multiple Doses of ISIS 353512 in Healthy Volunteers
The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of ISIS 353512, to evaluate the blood concentration and rate elimination of ISIS 353512 from the blood, and to evaluate the…
- Trial name
- NCT00734240
- Testing
- ISIS 353512
- Where
- Canada
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Ionis Pharmaceuticals, Inc.
Type 2 Diabetes Mellitus
Placebo Controlled, Dose Escalation Study in Subjects With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea
The purpose of this study is to provide an initial assessment of the safety, tolerability and efficacy of ISIS 113715 in combination with sulfonylurea in type 2 diabetes subjects.
- Trial name
- NCT00455598
- Testing
- ISIS 113715
- Where
- 39 sites in Poland, Romania and 1 more
- Volunteers
- 88 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Type 2 Diabetes Mellitus
Safety Study of ISIS 325568 in Healthy Volunteers
The primary purpose of this trial is to assess the safety of ISIS 325568 when given at increasing single doses and to assess the safety of the same doses when given multiple times.
- Trial name
- NCT00519727
- Testing
- ISIS 325568
- Where
- Netherlands
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ionis Pharmaceuticals, Inc.
Type 2 Diabetes Mellitus
Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Who Have Not Received Prior Treatment
The aim of this study is to evaluate the safety, tolerability, and pharmacokinetics of five ISIS 113715 intravenous dose cohorts in drug-naïve type 2 diabetics.
- Trial name
- NCT00330330
- Testing
- ISIS 113715
- Where
- 10 sites in Poland, Russia
- Volunteers
- 96 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Type 2 Diabetes Mellitus
Examination of Dermatologic Effects From Subcutaneous Injections of ISIS 113715
10 healthy volunteers will be enrolled to each receive two subcutaneous injections of ISIS 113715 in the abdomen on Study Day 1. Each subject will receive their two injections within a 5-minute period.
- Trial name
- NCT00365781
- Testing
- ISIS 113715
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Ionis Pharmaceuticals, Inc.
Cytomegalovirus Retinitis, HIV Infections
The Safety and Effectiveness of ISIS 2922 in Patients With AIDS Who Have Cytomegalovirus (CMV) of the Eyes
To evaluate the efficacy and safety of ISIS 2922 in AIDS patients with Cytomegalovirus ( CMV ) retinitis who are unresponsive or intolerant to ganciclovir and/or foscarnet but are otherwise ineligible for ISIS Pharmaceuticals'…
- Trial name
- NCT00002356
- Testing
- Fomivirsen sodium
- Where
- 25 sites in United States
- Sponsor
- Ionis Pharmaceuticals, Inc.
Cytomegalovirus Retinitis, HIV Infections
A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR )
To determine the clinically safe and effective dose of intravitreal ISIS 2922 alone and as an additive antiviral therapy to ganciclovir in AIDS patients with cytomegalovirus (CMV) retinitis.
- Trial name
- NCT00002156
- Testing
- Fomivirsen sodium, Ganciclovir
- Where
- 18 sites in United States
- Volunteers
- 194 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Cytomegalovirus Retinitis, HIV Infections
A Comparison of ISIS 2922 Used Immediately or Later in Patients With Cytomegalovirus (CMV) of the Eyes
To determine a clinically safe and effective dose of intravitreally injected ISIS 2922 and to compare the safety and efficacy of immediate versus delayed treatment in AIDS patients with previously untreated, peripheral…
- Trial name
- NCT00002355
- Testing
- Fomivirsen sodium
- Where
- 13 sites in United States
- Volunteers
- 60 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Cytomegalovirus Retinitis, HIV Infections
A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis
The purpose of this study is to compare the safety and effectiveness of two dosage schedules for ISIS 2922 in the treatment of advanced cytomegalovirus (CMV) retinitis
- Trial name
- NCT00002187
- Testing
- Fomivirsen sodium
- Where
- 17 sites in United States
- Sponsor
- Ionis Pharmaceuticals, Inc.